BRIGHT MINDS BIOSCIENCES INC. (DRUG)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

54.05 on 9 Oct 2026

0 buys1 sale at will0 planned sales

Fiscal year 2024, ended 30 Sep 2024, as filed

Net income

$2.80M

Free cash flow

$1.85M

Return on equity

-50.6%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
28 Apr 2026	Cormorant Asset Management, LP Former 10% Owner	Sold at will	$9.79M	10.3%
4 Nov 2024	Cormorant Asset Management, LP 10% owner	Bought	$4.00M	21.1%
16 Oct 2024	Cormorant Asset Management, LP 10% owner	Bought	$1.17M	6.1%
15 Oct 2024	Cormorant Asset Management, LP 10% owner	Bought	$2.06M	82.4%

33out of 100

Profitability 0

Financial strength 70

Growth n/a

Insiders 35

Strongest on financial strength (70), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$9.79M

1 sale

Planned sales

under a 10b5-1 plan